sellWeak cluster of 4
Charles N York II sold $36k of DAWN
COO and CFO at Day One Biopharmaceuticals, Inc.. 4,062 shares at an average of $8.91, traded Nov 17, 2025, filed Nov 18, 2025.
Warning score
28Value
$36k
4,062 shares
Holdings after
294,715
-1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +6Trade size$36k at market
- 0Share of holdings soldSold 1.4% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001655962-25-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 15, 2025 | MOption exercise Common Stock | +1,375 | - | - | 283,277 | Nov 18, 2025 |
| Nov 15, 2025 | MOption exercise Common Stock | +2,250 | - | - | 285,527 | Nov 18, 2025 |
| Nov 15, 2025 | MOption exercise Common Stock | +6,625 | - | - | 292,152 | Nov 18, 2025 |
| Nov 15, 2025 | MOption exercise Common Stock | +6,625 | - | - | 298,777 | Nov 18, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stock | -4,062 | $8.91 | $36k | 294,715 | Nov 18, 2025 |
| Nov 15, 2025 | MOption exercise Restricted Stock Unit (RSU)derivative | -1,375 | $0.00 | $0 | 0 | Nov 18, 2025 |
| Nov 15, 2025 | MOption exercise Restricted Stock Unit (RSU)derivative | -2,250 | $0.00 | $0 | 9,000 | Nov 18, 2025 |
| Nov 15, 2025 | MOption exercise Restricted Stock Unit (RSU)derivative | -6,625 | $0.00 | $0 | 53,000 | Nov 18, 2025 |
| Nov 15, 2025 | MOption exercise Restricted Stock Unit (RSU)derivative | -6,625 | $0.00 | $0 | 79,500 | Nov 18, 2025 |
Related signals
Other insiders at Day One Biopharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | Day One Biopharmaceuticals, Inc. | Jeremy Bender CHIEF EXECUTIVE OFFICER | $179k 15,459 shares | -7% | |
| 30Weak | Day One Biopharmaceuticals, Inc. | Charles N York II COO and CFO | $70k 6,065 shares | -2% | |
| 30Weak | Day One Biopharmaceuticals, Inc. | Michael Vasconcelles Head of Research and Dev. | $32k 2,728 shares | -38% | |
| 23Weak | Day One Biopharmaceuticals, Inc. | Adam Dubow Gen Counsel & Secretary | $74k 6,395 shares | -8% | |
| 23Weak | Day One Biopharmaceuticals, Inc. | Lauren Merendino Chief Commercial Officer | $67k 5,814 shares | -9% | |
| 36Weak | Day One Biopharmaceuticals, Inc. | Jeremy Bender CHIEF EXECUTIVE OFFICER | $142k 15,894 shares | -8% | |
| 21Weak | Day One Biopharmaceuticals, Inc. | Adam Dubow Gen Counsel & Secretary | $39k 4,319 shares | -6% | |
| 21Weak | Day One Biopharmaceuticals, Inc. | Lauren Merendino Chief Commercial Officer | $33k 3,726 shares | -7% | |
| 35Weak | Day One Biopharmaceuticals, Inc. | Jeremy Bender CHIEF EXECUTIVE OFFICER | $109k 16,058 shares | -9% | |
| 20Weak | Day One Biopharmaceuticals, Inc. | Lauren Merendino Chief Commercial Officer | $25k 3,766 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.